Literature DB >> 15358305

Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.

Robert A Parise1, Barney R Sparrow, John W Merrill, Irma M Grossi, Joseph M Covey, James O Peggins, Merrill J Egorin.   

Abstract

An LC-MS/MS method was developed to quantitate the potential antitumor agent halofuginone in plasma. The assay uses 0.2 ml of plasma; chlorohalofuginone internal standard; acetonitrile for protein precipitation; a Phenomenex SYNERGI 4 micro Polar RP 80A (4 microm, 100 mm x 2 mm) column; an isocratic mobile phase of methanol:water:formic acid (80:20:0.02, v/v/v); and positive-ion electrospray ionization with selective reaction monitoring detection. Halofuginone eluted at approximately 2.4 min, internal standard eluted at approximately 2.9 min, and no endogenous materials interfered with their measurement. The assay was accurate, precise, and linear between 0.1 and 100 ng/ml. Halofuginone could be quantitated in dog plasma for at least 24 h after an i.v. dose of 0.1mg/kg. The assay is being used in ongoing pharmacokinetic studies of halofuginone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358305     DOI: 10.1016/j.jchromb.2004.07.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  1 in total

1.  Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.

Authors:  Henry B Koon; Barbara Fingleton; Jeannette Y Lee; Julia T Geyer; Ethel Cesarman; Robert A Parise; Merrill J Egorin; Bruce J Dezube; David Aboulafia; Susan E Krown
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.